Rapid emergence of ESBL producers in E. coli causing urinary and wound infections in Pakistan

Pakistan Journal of Medical Sciences

Volumn 29, Issue 2, 2013, Pages

  Habeeb, Muhammad Asif ^a   Sarwar, Yasra ^a   Ali, Aamir ^a   Salman, Muhammad ^a   Haque, Abdul ^a  

^a NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

Author keywords

Coli; Drug resistance; ESBL production; Genotypic characterization; Pathogenic E

Indexed keywords

BETA LACTAMASE CTX M; BETA LACTAMASE OXA 1; BETA LACTAMASE OXA 10; BETA LACTAMASE OXA 2; BETA LACTAMASE SHV; BETA LACTAMASE TEM; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; TIMENTIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; CTX M GENE; DISK DIFFUSION; ENZYME SYNTHESIS; ESCHERICHIA COLI; MULTIDRUG RESISTANCE; NONHUMAN; PAKISTAN; PREVALENCE; PUS; TEM GENE; URINARY TRACT INFECTION; URINE; WOUND INFECTION;

EID: 84875088867     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.292.3144     Document Type: Article

References (20)

1. Bonnet R. Growing group of extended spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48(1):1-14.
2. Bonnedahl J, Drobni M, Gauthier-Clerc M. Dissemination of Escherichia coli with CTX-M type ESBL between humans and yellow-legged gulls in the south of France. PLoS One. 2009;4(6):e5958.
3. Livermore DM, Canton R, Gniadkowski M. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59(2):165-174.
4. Pitout JD. Infections with extended spectrum β-lactamaseproducing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313-333.
5. Coque TM, Novais A, Carattoli A. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis. 2008;14(2):195-200.
6. Doi Y, Adams J, O'Keefe A. Community-acquired extendedspectrum β-lactamase producers, United States. Emerg Infect Dis. 2007;13(7):1121-1123.
7. Hussain M, Hasan F, Shah AA. Prevalence of class A and AmpC β-lactamases in clinical Escherichia coli isolates from Pakistan Institute of Medical Science, Islamabad, Pakistan. Jpn J Infect Dis. 2011;64(3):249-252.
8. CLSI. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing 222nd informational supplement M100-S22 CLSI, Wayne, PA. 2012.
9. Sambrook J, Rusell DW. Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory, 2001.
10. Mulvey MR, Soule G, Boyd D. Characterization of the first extended spectrum β-lactamase-producing Salmonella isolate identified in Canada. J Clin Microbiol. 2003;41(1):460-462.
11. Lim KT, Yasin R, Yeo CC. Characterization of multidrug resistant ESBL-producing Escherichia coli isolates from hospitals in Malaysia. J Biomed Biotechnol. 2009;2009:165637.
12. Oliver A, Weigel LM, Rasheed JK. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother. 2002;46(12):3829-3836.
13. Shiraki Y, Shibata N, Doi Y. Escherichia coli producing CTX-M-2 β-lactamase in cattle, Japan. Emerg Infect Dis. 2004;10(1):69-75.
14. Luzzaro F, Mezzatesta M, Mugnaioli C. Trends in production of extended spectrum β-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol. 2006;44(5):1659-1664.
15. Abreu AG, Marques SG, Monteiro-Neto V. Nosocomial infection and characterization of extended spectrum β-lactamases-producing Enterobacteriaceae in Northeast Brazil. Rev Soc Bras Med Trop. 2011;44(4):441-446.
16. Mshana SE, Kamugisha E, Mirambo M. Prevalence of multiresistant gram-negative organisms in a tertiary hospital in Mwanza, Tanzania. BMC Res Notes. 2009;2:49.
17. Jones CH, Tuckman M, Keeney D. Characterization and sequence analysis of extended-spectrum β-lactamaseencoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob Agents Chemother. 2009;53(2):465-475.
18. Idowu OJ, Onipede AO, Orimolade AE. Extended spectrum β lactamase Orthopedic Wound Infections in Nigeria. J Glob Infect Dis. 2011;3(3):211-215.
19. Falagas ME, Kastoris AC, Kapaskelis AM. Fosfomycin for the treatment of multidrug resistant, including extended spectrum β lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis. 2010;10(1):43-50.
20. Paterson DL, Ko WC, Von Gottberg A. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended spectrum β-lactamases. Clin Infect Dis. 2004;39(1):31-37.